Institute for Clinical and Economic Review Publishes Evidence Report on Therapies for Lupus Nephritis
March 13, 2021
March 13, 2021
BOSTON, Massachusetts, March 13 (TNSRep) -- The Institute for Clinical and Economic Review issued the following announcement on March 12, 2021:
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of belimumab (Benlysta(R), GlaxoSmithKline) and voclosporin (Lupkynis(TM), Aurinia) for the treatment of lupus nephritis (LN). The FDA approved belimumab on December 17, 2020 and voclosporin on Ja . . .
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of belimumab (Benlysta(R), GlaxoSmithKline) and voclosporin (Lupkynis(TM), Aurinia) for the treatment of lupus nephritis (LN). The FDA approved belimumab on December 17, 2020 and voclosporin on Ja . . .